OBJECTIVES: To assess the impact of LSRs on resource use and quality of life (QoL) associated with different field therapies for actinic keratoses (AK) on face or scalp in Belgium. METHODS: A structured written questionnaire was completed by 33 Belgian dermatologists from all country regions. All had experience with topical field therapies ingenol mebutate (IMB), imiquimod (IMI) and 5-Fluorouracil (5-FU); 60% had access to photodynamic therapy + methylaminolevulinate (PDT). RESULTS: Treatment duration is 3 days, 4 weeks, 4-6 weeks and 1 day with IMB, IMI, 5-FU and PDT respectively. The average (2.5^th-97.5^th percentile) number of dermatologist visits per treatment (including unplanned visits for local skin reactions (LSRs)) was 2.91 (2.0-4.56), 3.43 (2.0-6.0), 3.14 (2.0-4.7) and 3.63 (2.0-5.4) respectively. Reported premature treatment discontinuation rates due to LSRs were lower for shorter regimens: 5.76% (0%-34%), 26.03% (0.7%-60%), 19.48% (0%-53%) and 8.00% (0%-25%) respectively. Duration of LSRs was also reported to be lower with shorter treatment regimens: 8.25 (2.78-14.23), 18.42 (6.50-6.00), 19.13 (2.90-65.50) and 7.81 (2.00-22.00) days respectively. LSR-associated absenteeism rate and duration in professionally active AK patients was 11.7% (3.3 days), 49.5% (6.1 days), 18.7% (6.4 days) and 18.2% (1.9 days) respectively. From a list of skin disorders with published disease-specific disutilities, experts were asked to identify ≥1 diseases (if any) with assumed similar impact on QoL as LSRs. Based on the expert replies, the weighted average disutility of LSRs on face or scalp was estimated at -0.116. CONCLUSIONS: This Belgian expert survey suggests that IMB and PDT are associated with lower rates of discontinuation and absenteeism and lower duration of LSRs compared to 5-FU and IMI. These differences seem to correlate with treatment duration. Based on comparisons with other skin diseases, the survey suggests that LSRs due to field therapy on face or scalp have a substantial impact on QoL.